首页> 外文期刊>The Lancet >Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis.
【24h】

Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis.

机译:对脆弱拟杆菌的临床分离株对甲硝唑,共阿莫西拉夫和亚胺培南同时耐药。

获取原文
获取原文并翻译 | 示例
           

摘要

A blood-culture isolate of Bacteroides fragilis, taken from a woman after elective laparotomy, was resistant to metronidazole and had reduced susceptibility to imipenem and co-amoxiclav. After treatment with imipenem, pus drained from the pleural cavity yielded an identical isolate that had become highly resistant to imipenem and co-amoxiclav. Emergence of full resistance to the beta-lactam antibiotics was accompanied by a tenfold rise in the specific activity of a metallo-beta-lactamase. Clinicians need to be alert to simultaneous resistance to metronidazole, co-amoxiclav, and imipenem and development of high-level resistance to imipenem in B fragilis during treatment with this agent.
机译:选择性剖腹手术后从一名女性身上获得的脆弱拟杆菌的血培养分离株对甲硝唑具有抗药性,对亚胺培南和复氧合氨西拉夫的敏感性降低。用亚胺培南治疗后,从胸膜腔引流的脓液产生了完全相同的分离株,该分离株已对亚胺培南和复方阿莫昔芬高度耐药。对β-内酰胺类抗生素完全耐药的出现伴随着金属-β-内酰胺酶比活性的十倍上升。临床医生需要警惕在使用该药物治疗期间,易感性甲硝唑,共阿莫西拉夫和亚胺培南同时耐药,以及对脆弱型乙型杆菌对亚胺培南产生高水平耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号